GLPwatch
Papers (10389)
Page 145 of 174, ranked by citation count.
- Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.
- Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?
- A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes.
- Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes.
- Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide.
- Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
- Liraglutide: can it make a difference in the treatment of type 2 diabetes?
- Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.
- Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
- Insulin degludec + liraglutide: a complementary combination.
- [Comments on current guidelines of type 2 diabetes mellitus treatment].
- Semaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta‑analysis.
- Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis.
- Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
- Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.
- Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.
- Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.
- Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
- Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder.
- PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
- Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective.
- Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?
- Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems.
- Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.
- Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.
- Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome.
- Liraglutide-Conjugated Poly(methyl vinyl ether-<i>alt</i>-maleic acid)-Coated Core-Shell Upconversion Nanoparticles for Theranostics of Diabetes.
- Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
- Tirzepatide-Associated Euglycemic Diabetic Ketoacidosis in the Absence of Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
- TREATMENT OF DIABETES MELLITUS IN A GOLDEN LION TAMARIN (LEONTOPITHECUS ROSALIA) WITH THE GLUCAGON-LIKE PEPTIDE-1 MIMETIC EXENATIDE.
- Semaglutide in Patients Undergoing Anesthesia for Otolaryngologic Procedures.
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching.
- Current challenges in type 2 diabetes.
- Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study.
- Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study.
- Effects of exenatide on coronary stent's endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study.
- The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
- Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
- 68Ga-NODAGA-Exendin-4 PET/CT Findings in a Case of Metastatic Insulinoma With Refractory Hypoglycemia Controlled by 90Y Transarterial Radioembolization.
- The Potential Weight Loss Benefits Of Tirzepatide: A Double-Edged Sword?
- Glucagon-Like Peptide 1 Receptor Agonist Use and Vertebral Fracture Risk in Type 2 Diabetes.
- Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.
- Appendicitis After Initiation of Tirzepatide.
- Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis.
- The nuclear option for insulinomas.
- Regulation of nanoparticle exocytosis direction via receptors transfer: A novel strategy to enhance therapeutic efficacy of semaglutide.
- Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery.
- New Drug Capsule: Tirzepatide.
- Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
- Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients.
- Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.
- Liraglutide for weight management: benefits and risks.
- New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
- Lessons From LEADER - All-round Leadership.
- Is there a role for the incretin system in blood pressure regulation?
- Combined effect of continuous glucose monitoring and semaglutide: analysis of administrative claims.
- Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.